Xencor (NASDAQ:XNCR) Stock Price Up 4.9% – What’s Next?

Xencor, Inc. (NASDAQ:XNCR) shot up 4.9% during mid-day trading on Tuesday . The company traded as high as $9.39 and last traded at $9.38. 360,465 shares traded hands during trading, a decline of 41% from the average session volume of 615,783 shares. The stock had previously closed at $8.94.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on XNCR. Wells Fargo & Company reduced their price objective on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. StockNews.com cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $34.38.

Xencor Price Performance

The stock’s fifty day moving average price is $12.90 and its 200-day moving average price is $19.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The firm has a market cap of $673.26 million, a PE ratio of -2.99 and a beta of 0.90.

Xencor (NASDAQ:XNCR) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. As a group, equities analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Institutional Trading of Xencor

Hedge funds and other institutional investors have recently modified their holdings of the business. Sterling Capital Management LLC lifted its holdings in shares of Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,040 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Xencor during the fourth quarter worth $34,000. GAMMA Investing LLC boosted its position in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 508 shares during the period. KBC Group NV grew its stake in shares of Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 813 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in Xencor by 49.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 1,337 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.